Novo Nordisk (NYSE: NVO) and Kailera Therapeutics (NASDAQ: KLRA) have both taken significant hits recently, yet their GLP-1 pipelines remain compelling for long-term investors.
The GLP-1 pharmaceutical market is currently one of the fastest-growing segments in the entire drug industry, attracting competitors of all sizes.
Novo Nordisk has faced clinical setbacks over the past 18 months while also dealing with intensifying competition from Eli Lilly (NYSE: LLY), which has weighed heavily on its financial results.
Despite those headwinds, Novo Nordisk scored a major win in January by launching oral Wegovy, the first weight loss pill approved in the United States.
Oral Wegovy has proven to be a smashing success, with more than 80% of prescriptions coming from patients who had never previously taken GLP-1 medicines.
The pill has surpassed three million prescriptions in the U.S. and recently earned approval in the European Union, opening a significant new market for the drug.
Novo Nordisk’s pipeline also includes a pair of triple agonists, medicines that mimic the action of three separate gut hormones, which could meaningfully outperform existing dual-agonist therapies like Eli Lilly’s Zepbound.
One of those triple agonists, UBT251, is being developed in collaboration with China-based The United Laboratories International Holdings Limited and has already shown strong results in phase 2 studies.
Despite falling 29% over the past year, Novo Nordisk’s long-standing leadership in the GLP-1 market positions it well to benefit as demand for these medicines continues rising.
Kailera Therapeutics went public in April and has since declined by 23%, making it a riskier but potentially rewarding play on the GLP-1 boom.
The company currently has no products on the market, but its pipeline features KAI-9531, a dual GLP-1 and GIP agonist in both oral and subcutaneous formulations, alongside KAI-4729, a triple agonist, and KAI-7535, an investigational oral GLP-1 product.
Kailera recently announced that oral KAI-7535 posted strong phase 3 results in China, achieving a mean weight loss of up to 11.1% after 50 weeks of treatment.
The drug also helped patients with type 2 diabetes meaningfully lower their blood sugar levels, suggesting broad therapeutic potential beyond weight management alone.
Kailera will still need to complete late-stage clinical trials in the U.S. before KAI-7535 can earn domestic regulatory approval, meaning meaningful risk remains on the timeline.
With a market cap of $2.5 billion, Kailera does not need to outperform Eli Lilly or Novo Nordisk outright to deliver strong returns for investors willing to accept heightened volatility.
Results that are competitive and offer meaningful differentiation could allow Kailera to capture a valuable slice of a rapidly expanding global market over the coming years.
